HONG KONG – A Hong Kong-based biotechnology company that specializes in in-licensing products for marketing in China will work with a partner in South Korea and one in Europe in a late-stage clinical development program for the oncolytic immunotherapy Pexa-Vec (JX-594/TG6006).